Last10K.com

Glycomimetics Inc (GLYC) SEC Filing 10-K Annual Report for the fiscal year ending Saturday, December 31, 2022

Glycomimetics Inc

HISTORY TOOLS
CIK: 1007019 Ticker: GLYC
Document and Entity Information - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Mar. 27, 2023
Jun. 30, 2022
Document and Entity Information   
Document Type10-K  
Document Annual Reporttrue  
Document Transition Reportfalse  
Document Period End DateDec. 31, 2022  
Entity File Number001-36177  
Entity Registrant NameGlycoMimetics, Inc.  
Entity Incorporation, State or Country CodeDE  
Entity Tax Identification Number06-1686563  
Entity Address, Address Line One9708 Medical Center Drive  
Entity Address, City or TownRockville  
Entity Address, State or ProvinceMD  
Entity Address, Postal Zip Code20850  
City Area Code240  
Local Phone Number243-1201  
Title of 12(b) SecurityCommon Stock, $0.001 par value  
Trading SymbolGLYC  
Security Exchange NameNASDAQ  
Entity Well-known Seasoned IssuerNo  
Entity Voluntary FilersNo  
Entity Current Reporting StatusYes  
Entity Interactive Data CurrentYes  
Entity Filer CategoryNon-accelerated Filer  
Entity Small Businesstrue  
Entity Emerging Growth Companyfalse  
Entity Shell Companyfalse  
ICFR Auditor Attestation Flagfalse  
Entity Public Float  $ 30.9
Entity Common Stock, Shares Outstanding 64,245,224 
Document Fiscal Year Focus2022  
Document Fiscal Period FocusFY  
Entity Central Index Key0001253689  
Current Fiscal Year End Date--12-31  
Amendment Flagfalse  
Auditor Firm ID42  
Auditor NameErnst & Young LLP  
Auditor LocationBaltimore, Maryland  

View differences made from one year to another to evaluate Glycomimetics Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Glycomimetics Inc.

Continue

Assess how Glycomimetics Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Glycomimetics Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
Other
Filter Subcategory:
All
Expense
Product
Cash Flow
Earnings
Income
Other
Inside Glycomimetics Inc's 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Balance Sheets
Balance Sheets (Parenthetical)
Statements Of Cash Flows
Statements Of Operations And Comprehensive Loss
Statements Of Stockholders' Equity
Accrued Expenses
Accrued Expenses (Tables)
Accrued Expenses - Summary Of Accrued Expenses (Details)
Description Of The Business
Description Of The Business (Details)
Employee Benefit Plan
Employee Benefit Plan (Detail)
Income Taxes
Income Taxes (Tables)
Income Taxes - Nols And Carryforwards (Detail)
Income Taxes - Reconciliation Between Statutory Federal Income Tax Rate And Effective Income Tax Rate (Detail)
Income Taxes - Schedule Of Gross Deferred Tax Asset And Related Valuation Allowance (Detail)
Net Loss Per Common Share (Details)
Net Loss Per Share Of Common Stock
Net Loss Per Share Of Common Stock (Tables)
Operating Leases
Operating Leases (Details)
Operating Leases (Tables)
Operating Leases - Components Of Lease Expense (Details)
Operating Leases - Maturities Of Lease Liability (Details)
Prepaid Expenses And Other Current Assets
Prepaid Expenses And Other Current Assets (Tables)
Prepaid Expenses And Other Current Assets - Summary Of Prepaid Expenses And Other Current Assets (Details)
Property And Equipment
Property And Equipment (Details)
Property And Equipment (Tables)
Research And License Agreements
Research And License Agreements (Details)
Significant Accounting Policies (Policies)
Stockholders Equity (Tables)
Stockholders' Equity
Stockholders' Equity - Company's Stock Option Activity (Details)
Stockholders' Equity - Equity Offerings (Details)
Stockholders' Equity - Incentive Plans (Details)
Stockholders' Equity - Inducement Plan (Details)
Stockholders' Equity - Inducement Plan - Stock Option Activity (Details)
Stockholders' Equity - Stock-Based Compensation Expense (Details)
Stockholders' Equity - Summary Of Rsu Activity (Details)
Stockholders' Equity - Weighted-Average Assumptions (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Fair Value Measurements (Details)
Summary Of Significant Accounting Policies - Impairment Of Long-Lived Assets (Details)
Summary Of Significant Accounting Policies - Property And Equipment (Details)
Summary Of Significant Accounting Policies - Segment Information (Details)
Summary Of Significant Accounting Policies - Stock-Based Compensation (Details)
Ticker: GLYC
CIK: 1253689
Form Type: 10-K Annual Report
Accession Number: 0001558370-23-004864
Submitted to the SEC: Wed Mar 29 2023 8:31:08 AM EST
Accepted by the SEC: Wed Mar 29 2023
Period: Saturday, December 31, 2022
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/glyc/0001558370-23-004864.htm